Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Natalizumab for keeping patients out of HARRMS way?

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J.Cost-effectiveness analyses of natalizumab (tysabri Rm) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. PharmacoEconomics 26: 617-627, No. 7, 2008

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Natalizumab for keeping patients out of HARRMS way?. Pharmacoecon. Outcomes News 557, 4 (2008). https://doi.org/10.2165/00151234-200805570-00008

    Download citation

    Keywords

    • Public Health
    • Acetate
    • Multiple Sclerosis
    • Health Outcome
    • Cost Effectiveness